Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood… Read more
Genix Pharmaceuticals Corporation (GENPF) - Total Liabilities
Latest total liabilities as of January 2025: $1.35 Million USD
Based on the latest financial reports, Genix Pharmaceuticals Corporation (GENPF) has total liabilities worth $1.35 Million USD as of January 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genix Pharmaceuticals Corporation - Total Liabilities Trend (2017–2024)
This chart illustrates how Genix Pharmaceuticals Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genix Pharmaceuticals Corporation Competitors by Total Liabilities
The table below lists competitors of Genix Pharmaceuticals Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aben Gold Corp.
F:ML1
|
Germany | €333.13K |
|
VIP Gloves Ltd
AU:VIP
|
Australia | AU$7.64 Million |
|
Capitol Nusantara Indonesia
JK:CANI
|
Indonesia | Rp691.34 Billion |
|
TronicS Microsystems SA
PA:ALTRO
|
France | €17.73 Million |
|
Retail Food Group Limited
PINK:RFGPF
|
USA | $155.39 Million |
|
CohBar Inc
NASDAQ:CWBR
|
USA | $3.00 Million |
|
BAINS MER MONAC N
MU:RJ8
|
Germany | €534.38 Million |
|
Australian Pacific Coal Ltd
AU:AQC
|
Australia | AU$159.28 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Genix Pharmaceuticals Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 23.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genix Pharmaceuticals Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genix Pharmaceuticals Corporation (2017–2024)
The table below shows the annual total liabilities of Genix Pharmaceuticals Corporation from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-10-31 | $1.23 Million | -9.71% |
| 2023-10-31 | $1.36 Million | +29.17% |
| 2022-10-31 | $1.05 Million | +39.50% |
| 2021-10-31 | $755.19K | +54.16% |
| 2020-10-31 | $489.88K | +494.44% |
| 2019-10-31 | $82.41K | -24.50% |
| 2018-10-31 | $109.15K | -59.99% |
| 2017-10-31 | $272.80K | -- |